Orbimed Capital, Director: ARS Pharmaceuticals SPRY Sell · Filed 24/08/28

Trade details

Type: Insider sale
Amount: $1,088,035
Shares · price: 83,695 sh · $13.00 a share
Held after: 0 sh
Stock: ARS Pharmaceuticals SPRY
Person: Orbimed CapitalDirector
Trade date: 24/08/26
Filed: 24/08/28
Days to filing: 2 days

Sold 100.0% of holdings

Share of holding sold: 100.0%

ARS Pharmaceuticals trades, last 26 weeks

What else happened in ARS Pharmaceuticals around then

Filed or reported within 30 days of the trade day · 24/07/27~24/09/25

Orbimed Capital's recent trades

Orbimed CapitalShareholder
Planned saleEnliven Therapeutics
Planned sale
Enliven Therapeutics
ELVN
$1.4M
29,385 sh
$1.4M
Filed 06/22
Traded 06/22
Orbimed CapitalShareholder
Planned saleEnliven Therapeutics
Planned sale
Enliven Therapeutics
ELVN
$80.3K
1,747 sh
$80.3K
Filed 06/22
Traded 06/22
Orbimed CapitalShareholder
Planned saleEnliven Therapeutics
Planned sale
Enliven Therapeutics
ELVN
$433.9K
10,243 sh
$433.9K
Filed 06/15
Traded 06/15
Orbimed CapitalDirector
BuyPrelude Therapeutics
Buy
Prelude Therapeutics
PRLD
$7.5M
1,689,189 sh
$7.5M
Filed 04/23
Traded 04/21
Orbimed CapitalDirector
BuyPrelude Therapeutics
Buy
Prelude Therapeutics
PRLD
$5M
1,126,126 sh
$5M
Filed 04/23
Traded 04/21